Subsequent Event - Additional Information (Details) - BioNova Option Agreement - Subsequent Event |
Oct. 09, 2021
USD ($)
|
|---|---|
| Subsequent Event [Line Items] | |
| Initial Licensing Option Payment | $ 4,000,000 |
| Maximum potential payments related to option exercise, development, regulatory, and commercial milestones | $ 200,000,000 |
| Minimum term of royalties receivable based on annual net sales | 10 years |
| X | ||||||||||
- Definition Initial licensing option payment. No definition available.
|
| X | ||||||||||
- Definition Maximum potential payments related to option exercise, development, regulatory, and commercial milestones. No definition available.
|
| X | ||||||||||
- Definition Minimum term of royalties receivable based on annual net sales. No definition available.
|
| X | ||||||||||
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|